Doxorubicin Hydrochloride for Injection

The drug can penetrate into cells and bind to chromosomes. Experiments have shown that the planar ring of doxorubicin inserts between base pairs to form a complex with DNA, which severely interferes with DNA synthesis, DNA-dependent RNA synthesis and protein synthesis. However, the concentration of doxorubicin required to produce antiproliferative effects through this mechanism is higher than the drug concentration at the tumor site during clinical treatment. Recent experiments have shown that drug insertion into DNA triggers topoisomerase II to cleave DNA, thereby destroying the tertiary structure of DNA. This effect can be seen at the drug concentration used in clinical treatment. Doxorubicin is also associated with oxidation/reduction: a series of NADPH-dependent cellular reductases can reduce doxorubicin to semiquinone free radicals, which then react with molecular oxygen to produce highly reactive cytotoxic compounds such as peroxides, active hydroxyl radicals and hydrogen peroxide. Free radical formation is associated with the cytotoxic effect of doxorubicin. Further sites of action of doxorubicin may be on the cell membrane: binding to lipids on the cell membrane affects a variety of different functions. The cytotoxic and/or antiproliferative effects of doxorubicin may be the result of any of the above mechanisms, and there may be other mechanisms of action. Studies have shown that doxorubicin is active throughout the cell cycle, including in the interphase, so rapidly proliferating tissues such as tumor tissue (but also bone marrow, gastrointestinal tract and mucosa, hair follicles) are most sensitive to the antiproliferative effects of doxorubicin.

The chemical name is: (8S,10S)-10-(3-amino-2,3,6-tridehydroxy-*-L-lyso-hexopyranoside)-8-ethanolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthalenedione hydrochloride. Molecular formula: C27H29O11N

This product is a loose mass with a slightly orange-red color.

Antimitotic and cytotoxic drugs. Doxorubicin can successfully induce remission in a variety of malignant tumors.

When preparing the solution, dissolve the contents of each vial with 5 ml of water for injection or sodium chloride injection. After adding the dissolving solution, shake the vial gently for half a minute to dissolve the contents, but do not invert the vial. Adults and children [intravenous administration]: This is the most commonly used route of administration. The prepared solution is infused intravenously through an unobstructed infusion tube for about 2-3 minutes. This can reduce the risk of thrombosis and cellulitis and blisters caused by drug spillage. Commonly used solutions are sodium chloride injection, 5% glucose injection, or sodium chloride glucose injection. The dosage is usually calculated based on body surface area. Usually when doxorubicin is used alone, it is administered once every three weeks at 60-75 mg/m2. When used in combination with other anti-tumor agents with repeated toxicity, the dose of doxorubicin must be reduced.

1 Bone marrow suppression and oral ulcers. Do not reuse this product when there is bone marrow suppression and oral ulcers. The latter may have a precursor symptom of oral burning sensation, and should not be used when symptoms occur. Obvious bone marrow suppression may occur about 10 days after the use of doxorubicin, so blood counts should be routinely monitored regardless of whether the patient has a blood disease or a non-blood disease. 2 Cardiotoxicity. Cardiotoxicity can manifest as bradycardia, including supraventricular bradycardia and electrocardiogram changes. It is recommended to routinely monitor the electrocardiogram. Patients with existing cardiac impairment should be particularly careful. When the cumulative dose exceeds 450-500 mg/m2, special care should be taken. When this dose level is exceeded, the risk of irreversible congestive heart failure is greatly increased. When considering the total amount of doxorubicin used, a comprehensive assessment should be made of the patient's previous or concurrent use of other drugs with obvious cardiotoxicity, such as high-dose intravenous cyclophosphamide, mediastinal radiotherapy, or related anthracycline compounds such as daunorubicin. Weekly dosing of doxorubicin has been shown to be less cardiotoxic than dosing it every three weeks, allowing patients to receive higher cumulative doses of treatment. It is important to note that heart failure can occur a few weeks after medication and may not respond to treatment. It is recommended to test the baseline electrocardiogram and follow up with an electrocardiogram during and immediately after medication. Transient electrocardiogram changes, such as flat T waves, S-T segment depression, and arrhythmias, are not considered an indication to stop using the drug. It is now believed that a decrease in the QRS wave is a more specific manifestation of cardiotoxicity. If this change occurs, the benefits of continuing medication treatment must be carefully weighed against the risk of irreversible heart damage. Severe heart failure can occur suddenly without prior electrocardiogram changes. 3 Rapid-dissolving doxorubicin hydrochloride for injection can make urine red, especially in the first urine after injection. Patients should be informed not to panic. 4 Gastrointestinal reactions: vomiting, nausea, and diarrhea may also occur. 5 Others: Abnormal liver and kidney function and hair loss are also common phenomena, including interference with beard growth, but all hair will resume normal growth after stopping the medication.

Patients with severe organic heart disease and abnormal cardiac function and those who are allergic to this product and anthracyclines are contraindicated. 1. Contraindications to intravenous administration: due to previous cytotoxic drug treatment, persistent bone marrow suppression or severe oral ulcers, systemic infection, obvious liver damage, severe arrhythmia, myocardial insufficiency, previous myocardial infarction, and the maximum cumulative dose of the drug has been used in previous anthracycline treatment. 2. Contraindications to intravesical instillation: invasive tumors have penetrated the bladder wall, urinary tract infection, bladder inflammation, and difficulty in catheter insertion (such as due to huge intravesical tumors).

When used in combination with cimetidine, the metabolism of this product can be slowed down. Taking it with foods high in tyramine (such as cheese) may cause high blood pressure.

Shade from light, store in a sealed container

10mg (calculated as C27H29NO11.HCl)

ShenZhen Main Luck Pharmaceuticals Inc

• Founded in:

  1990-07-04

• Address:

  Wanle Pharmaceutical Building, National Biomedicine Industry Base, Lanzhu East Road, Pingshan New District, Shenzhen

• Tax NO.:

  91440300618861849X

• Registered Funds:

  $19,544,550

• Website:

  Log in to view

• Email:

  Log in to view